ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.
한글목차
토파시티닙 시장 규모는 최근 급성장하고 있습니다. 2025년 34억 2,000만 달러에서 2026년에는 38억 6,000만 달러에 이르고, CAGR 12.9%의 성장이 전망되고 있습니다. 지난 몇 년간의 성장은 류마티스 관절염 환자 증가, 궤양성 대장염에 대한 인식 증가, 생물학적 제제 시장 확대, 야누스 키나아제 억제제 승인, 병원 약국 네트워크의 성장에 기인하는 것으로 보입니다.
토파시티닙 시장 규모는 향후 몇 년간 급성장이 전망됩니다. 2030년에는 65억 3,000만 달러에 이르고, CAGR은 14.0%를 나타낼 전망입니다. 예측 기간의 성장 요인으로는 신규 토파시티닙 제제 개발, 정밀의료에 대한 관심 증가, 바이오시밀러에 대한 투자 증가, 온라인 약국 채널 확대, 면역억제제에 대한 수요 증가 등을 꼽을 수 있습니다. 예측 기간의 주요 동향으로는 표적치료제 도입 확대, 궤양성 대장염 및 류마티스 질환의 유병률 증가, 맞춤형 의료로의 전환, 바이오의약품 R&D 투자 증가, 전문약국 확대 등이 있습니다.
염증성 장질환(IBD) 환자 수 증가는 향후 몇 년간 토파시티닙 시장의 성장을 견인할 것으로 예측됩니다. IBD는 소화관의 만성 염증성 질환군으로 주로 크론병과 궤양성 대장염을 포함합니다. 토파시티닙은 야누스 키나아제(JAK) 효소를 억제하여 증상을 완화하고 점막 치유를 촉진함으로써 IBD 관리에 사용됩니다. 예를 들어, 2023년 6월 기준, 비영리단체 '크론병 및 대장염 캐나다'는 32만 2,600명 이상의 캐나다인이 IBD를 앓고 있는 것으로 추정하고 있으며, 이는 전체 인구의 약 0.82%에 해당합니다. 이 유병률은 증가 추세에 있으며, 2035년까지 약 47만 명의 캐나다인이 IBD를 앓게 될 것으로 예측됩니다. 이는 인구의 약 1.1%, 즉 91명 중 1명에 해당합니다. 따라서 IBD 증가 추세는 토파시티닙 시장의 성장을 견인하고 있습니다.
토파시티닙 시장의 주요 기업들은 경쟁 우위를 확보하기 위해 외용제 개발에 집중하고 있습니다. 토파시티닙 외용제는 피부에 직접 도포할 수 있도록 설계되었습니다. 예를 들어, 2023년 6월 인도에 본사를 둔 제약사 인테스 파마슈티컬스(Intas Pharmaceuticals)는 경증 및 중등도 아토피피부염(AD) 치료제인 토파시티닙 외용제(JAK 억제제)를 인도에서 출시했습니다. 이는 국내 최초로 AD 치료제로 승인된 JAK 억제제입니다. 인도인 AD 환자를 대상으로 한 TOFATAS(토파시티닙 연고 2% w/w) 임상 3상 시험에서 높은 안전성과 유효성을 확인했습니다. TOFATAS의 출시로 인도에서 승인된 외용 JAK 억제제가 없었던 AD 환자들에게 새로운 치료 옵션을 제공할 수 있게 됐습니다.
목차
제1장 주요 요약
제2장 시장 특징
제3장 시장 공급망 분석
제4장 세계 시장 동향과 전략
제5장 최종 이용 산업 시장 분석
제6장 시장 : 금리, 인플레이션, 지정학, 무역 전쟁과 관세의 영향, 관세 전쟁과 무역 보호주의의 공급망에 대한 영향, 코로나 팬데믹이 시장에 미치는 영향을 포함한 거시경제 시나리오
제7장 세계 전략 분석 프레임워크, 현재 시장 규모, 시장 비교 및 성장률 분석
제8장 TAM(Total Addressable Market) 규모
제9장 시장 세분화
제10장 지역별/국가별 분석
제11장 아시아태평양 시장
제12장 중국 시장
제13장 인도 시장
제14장 일본 시장
제15장 호주 시장
제16장 인도네시아 시장
제17장 한국 시장
제18장 대만 시장
제19장 동남아시아 시장
제20장 서유럽 시장
제21장 영국 시장
제22장 독일 시장
제23장 프랑스 시장
제24장 이탈리아 시장
제25장 스페인 시장
제26장 동유럽 시장
제27장 러시아 시장
제28장 북미 시장
제29장 미국 시장
제30장 캐나다 시장
제31장 남미 시장
제32장 브라질 시장
제33장 중동 시장
제34장 아프리카 시장
제35장 시장 규제 상황과 투자환경
제36장 경쟁 구도와 기업 개요
제37장 기타 주요 기업 및 혁신 기업
제38장 세계 시장 경쟁 벤치마킹과 대시보드
제39장 주요 인수합병(M&A)
제40장 시장 잠재력이 높은 국가, 부문, 전략
제41장 부록
LSH
영문 목차
영문목차
Tofacitinib is a medication used to treat ulcerative colitis and other rheumatic conditions, including rheumatoid arthritis and ankylosing spondylitis. It is prescribed for moderate to severely active ulcerative colitis in patients who are intolerant of, respond poorly to, or lose response to biological therapy or conventional treatments.
The main drug classes of tofacitinib include antirheumatic, Janus kinase inhibitor, and immunosuppressant. Antirheumatic drugs are medications used to manage rheumatism. Available strengths include 5 mg, 10 mg, 11 mg, and 22 mg, administered orally and via other routes. Tofacitinib is distributed through hospital pharmacies, retail pharmacies, and online pharmacies for conditions such as ulcerative colitis, rheumatoid arthritis, psoriasis, and other related diseases.
Tariffs have influenced the tofacitinib market by affecting the import and export of active pharmaceutical ingredients (APIs) and raw materials, leading to increased production costs. The impact is most pronounced in regions such as Asia-Pacific and Europe, where major manufacturing and supply chain hubs exist, particularly for hospital and retail pharmacy segments. While tariffs may slow the entry of lower-cost alternatives, they also encourage local production and innovation, creating opportunities for domestic manufacturers to strengthen their market presence and improve supply chain resilience.
The tofacitinib market research report is one of a series of new reports from The Business Research Company that provides tofacitinib market statistics, including tofacitinib industry global market size, regional shares, competitors with a tofacitinib market share, detailed tofacitinib market segments, market trends and opportunities, and any further data you may need to thrive in the tofacitinib industry. This tofacitinib market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The tofacitinib market size has grown rapidly in recent years. It will grow from $3.42 billion in 2025 to $3.86 billion in 2026 at a compound annual growth rate (CAGR) of 12.9%. The growth in the historic period can be attributed to rising cases of rheumatoid arthritis, increasing awareness of ulcerative colitis, expansion of biologics market, approval of janus kinase inhibitors, growth of hospital pharmacy networks.
The tofacitinib market size is expected to see rapid growth in the next few years. It will grow to $6.53 billion in 2030 at a compound annual growth rate (CAGR) of 14.0%. The growth in the forecast period can be attributed to development of novel tofacitinib formulations, growing focus on precision medicine, increasing investment in biosimilars, expansion of online pharmacy channels, rising demand for immunosuppressants. Major trends in the forecast period include increasing adoption of targeted therapies, rising prevalence of ulcerative colitis and rheumatic diseases, shift towards personalized medicine, growing biopharmaceutical r&d investments, expansion of specialty pharmacies.
The rising number of patients with inflammatory bowel disease (IBD) is expected to drive the growth of the tofacitinib market in the coming years. IBD is a group of chronic inflammatory disorders of the gastrointestinal tract, primarily including Crohn's disease and ulcerative colitis. Tofacitinib is used to manage IBD by inhibiting Janus kinase (JAK) enzymes, reducing symptoms, and promoting mucosal healing. For example, in June 2023, Crohn's and Colitis Canada, a non-profit organization, estimated that over 322,600 Canadians were living with IBD, representing approximately 0.82% of the population. The prevalence is projected to rise, with around 470,000 Canadians expected to have IBD by 2035, accounting for roughly 1.1% of the population, or 1 in every 91 individuals. Consequently, the increasing prevalence of IBD is fueling the growth of the tofacitinib market.
Leading companies in the tofacitinib market are focusing on developing topical formulations to gain a competitive advantage. Topical tofacitinib is designed for application directly to the skin. For instance, in June 2023, Intas Pharmaceuticals, an India-based pharmaceutical company, launched Tofacitinib Topical (JAKi) for treating mild to moderate atopic dermatitis (AD) in India. This marked the first JAK inhibitor approved for AD in the country. A Phase III clinical study of TOFATAS (Tofacitinib Ointment 2% w/w) in Indian AD patients demonstrated significant safety and efficacy. The launch of TOFATAS provides a new treatment option for AD patients, as no topical JAK inhibitors were previously approved in India.
In January 2025, Fiocruz, a Brazil-based public health institution specializing in research, development, and production of vaccines and medicines, partnered with Pfizer Inc. to produce a generic version of Xeljanz (Tofacitinib) in Brazil. This collaboration aims to expand local access to advanced rheumatoid arthritis therapies while allowing Pfizer to strengthen its presence and improve patient access in the country. Pfizer Inc. is a US-based manufacturer of tofacitinib.
Major companies operating in the tofacitinib market are Pfizer Inc, Beacon Pharmaceuticals Limited, Glenmark Pharmaceuticals LTD, Sun Pharmaceutical Industries Ltd, Zydus Lifesciences Ltd, Unichem Laboratories, Sandoz International GmbH, Mylan N.V., Hetero Drugs Limited, Torrent Pharmaceuticals Ltd, Lupin Limited, Aurobindo Pharma Limited, Cipla Inc, Dr. Reddys Laboratories Ltd, Strides Pharma Science Limited, Alkem Laboratories Limited, Cadila Healthcare Limited, Wockhardt Limited, Alembic Pharmaceuticals Limited, Intas Pharmaceuticals Limited
North America was the largest region in the tofacitinib market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the tofacitinib market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
The countries covered in the tofacitinib market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
The tofacitinib market consists of sales of Xeljanz and Xeljanz XR. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Tofacitinib Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.
This report focuses tofacitinib market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
Create regional and country strategies on the basis of local data and analysis.
Identify growth segments for investment.
Outperform competitors using forecast data and the drivers and trends shaping the market.
Understand customers based on end user analysis.
Benchmark performance against key competitors based on market share, innovation, and brand strength.
Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
All data from the report will also be delivered in an excel dashboard format.
Where is the largest and fastest growing market for tofacitinib ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The tofacitinib market global report from the Business Research Company answers all these questions and many more.
The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.
The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
Market segmentations break down the market into sub markets.
The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Scope
Markets Covered:1) By Drug Class: Antirheumatic; Janus Kinase Inhibitor; Immunosuppressant
2) By Strength: 5mg; 10mg; 11mg; 22mg
3) By Route Of Administration: Oral; Other Routes Of Administration
4) By Distribution Channel: Hospital Pharmacy; Retail Pharmacy; Online Pharmacy
5) By Application: Ulcerative Colitis; Rheumatoid Arthritis; Psoriasis; Other Applications
Subsegments:
1) By Antirheumatic: Conventional Synthetic Antirheumatics; Targeted Synthetic Antirheumatics
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report
+ Excel Dashboard
Added Benefits
Bi-Annual Data Update
Customisation
Expert Consultant Support
Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.
4.2.2 Rising Prevalence Of Ulcerative Colitis And Rheumatic Diseases
4.2.3 Shift Towards Personalized Medicine
4.2.4 Growing Biopharmaceutical R&D Investments
4.2.5 Expansion Of Specialty Pharmacies
5. Tofacitinib Market Analysis Of End Use Industries
5.1 Hospitals
5.2 Specialty Clinics
5.3 Retail Pharmacies
5.4 Online Pharmacies
5.5 Research Institutes
6. Tofacitinib Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, Supply Chain Impact from Tariff War & Trade Protectionism, And Covid And Recovery On The Market
7. Global Tofacitinib Strategic Analysis Framework, Current Market Size, Market Comparisons And Growth Rate Analysis
7.1. Global Tofacitinib PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
7.2. Global Tofacitinib Market Size, Comparisons And Growth Rate Analysis
7.3. Global Tofacitinib Historic Market Size and Growth, 2020 - 2025, Value ($ Billion)
7.4. Global Tofacitinib Forecast Market Size and Growth, 2025 - 2030, 2035F, Value ($ Billion)
8. Global Tofacitinib Total Addressable Market (TAM) Analysis for the Market
8.1. Definition and Scope of Total Addressable Market (TAM)
8.2. Methodology and Assumptions
8.3. Global Total Addressable Market (TAM) Estimation
8.4. TAM vs. Current Market Size Analysis
8.5. Strategic Insights and Growth Opportunities from TAM Analysis
9. Tofacitinib Market Segmentation
9.1. Global Tofacitinib Market, Segmentation By Drug Class, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
9.7. Global Tofacitinib Market, Sub-Segmentation Of Janus Kinase Inhibitor, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
JAK1 Inhibitors, JAK2 Inhibitors, JAK3 Inhibitors
9.8. Global Tofacitinib Market, Sub-Segmentation Of Immunosuppressant, By Type, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
Corticosteroids, Non-Steroidal Immunosuppressants
10. Tofacitinib Market Regional And Country Analysis
10.1. Global Tofacitinib Market, Split By Region, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
10.2. Global Tofacitinib Market, Split By Country, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
11. Asia-Pacific Tofacitinib Market
11.1. Asia-Pacific Tofacitinib Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
11.2. Asia-Pacific Tofacitinib Market, Segmentation By Drug Class, Segmentation By Strength, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
12. China Tofacitinib Market
12.1. China Tofacitinib Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
12.2. China Tofacitinib Market, Segmentation By Drug Class, Segmentation By Strength, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
13. India Tofacitinib Market
13.1. India Tofacitinib Market, Segmentation By Drug Class, Segmentation By Strength, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
14. Japan Tofacitinib Market
14.1. Japan Tofacitinib Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
14.2. Japan Tofacitinib Market, Segmentation By Drug Class, Segmentation By Strength, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
15. Australia Tofacitinib Market
15.1. Australia Tofacitinib Market, Segmentation By Drug Class, Segmentation By Strength, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
16. Indonesia Tofacitinib Market
16.1. Indonesia Tofacitinib Market, Segmentation By Drug Class, Segmentation By Strength, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
17. South Korea Tofacitinib Market
17.1. South Korea Tofacitinib Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
17.2. South Korea Tofacitinib Market, Segmentation By Drug Class, Segmentation By Strength, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
18. Taiwan Tofacitinib Market
18.1. Taiwan Tofacitinib Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
18.2. Taiwan Tofacitinib Market, Segmentation By Drug Class, Segmentation By Strength, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
19. South East Asia Tofacitinib Market
19.1. South East Asia Tofacitinib Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
19.2. South East Asia Tofacitinib Market, Segmentation By Drug Class, Segmentation By Strength, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
20. Western Europe Tofacitinib Market
20.1. Western Europe Tofacitinib Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
20.2. Western Europe Tofacitinib Market, Segmentation By Drug Class, Segmentation By Strength, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
21. UK Tofacitinib Market
21.1. UK Tofacitinib Market, Segmentation By Drug Class, Segmentation By Strength, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
22. Germany Tofacitinib Market
22.1. Germany Tofacitinib Market, Segmentation By Drug Class, Segmentation By Strength, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
23. France Tofacitinib Market
23.1. France Tofacitinib Market, Segmentation By Drug Class, Segmentation By Strength, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
24. Italy Tofacitinib Market
24.1. Italy Tofacitinib Market, Segmentation By Drug Class, Segmentation By Strength, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
25. Spain Tofacitinib Market
25.1. Spain Tofacitinib Market, Segmentation By Drug Class, Segmentation By Strength, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
26. Eastern Europe Tofacitinib Market
26.1. Eastern Europe Tofacitinib Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
26.2. Eastern Europe Tofacitinib Market, Segmentation By Drug Class, Segmentation By Strength, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
27. Russia Tofacitinib Market
27.1. Russia Tofacitinib Market, Segmentation By Drug Class, Segmentation By Strength, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
28. North America Tofacitinib Market
28.1. North America Tofacitinib Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
28.2. North America Tofacitinib Market, Segmentation By Drug Class, Segmentation By Strength, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
29. USA Tofacitinib Market
29.1. USA Tofacitinib Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
29.2. USA Tofacitinib Market, Segmentation By Drug Class, Segmentation By Strength, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
30. Canada Tofacitinib Market
30.1. Canada Tofacitinib Market Overview
Country Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
30.2. Canada Tofacitinib Market, Segmentation By Drug Class, Segmentation By Strength, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
31. South America Tofacitinib Market
31.1. South America Tofacitinib Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
31.2. South America Tofacitinib Market, Segmentation By Drug Class, Segmentation By Strength, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
32. Brazil Tofacitinib Market
32.1. Brazil Tofacitinib Market, Segmentation By Drug Class, Segmentation By Strength, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
33. Middle East Tofacitinib Market
33.1. Middle East Tofacitinib Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
33.2. Middle East Tofacitinib Market, Segmentation By Drug Class, Segmentation By Strength, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
34. Africa Tofacitinib Market
34.1. Africa Tofacitinib Market Overview
Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
34.2. Africa Tofacitinib Market, Segmentation By Drug Class, Segmentation By Strength, Segmentation By Route Of Administration, Historic and Forecast, 2020-2025, 2025-2030F, 2035F, $ Billion
35. Tofacitinib Market Regulatory and Investment Landscape
36. Tofacitinib Market Competitive Landscape And Company Profiles
36.1. Tofacitinib Market Competitive Landscape And Market Share 2024
36.1.1. Top 10 Companies (Ranked by revenue/share)
36.2. Tofacitinib Market - Company Scoring Matrix
36.2.1. Market Revenues
36.2.2. Product Innovation Score
36.2.3. Brand Recognition
36.3. Tofacitinib Market Company Profiles
36.3.1. Pfizer Inc Overview, Products and Services, Strategy and Financial Analysis
36.3.2. Beacon Pharmaceuticals Limited Overview, Products and Services, Strategy and Financial Analysis
36.3.3. Glenmark Pharmaceuticals LTD Overview, Products and Services, Strategy and Financial Analysis
36.3.4. Sun Pharmaceutical Industries Ltd Overview, Products and Services, Strategy and Financial Analysis
36.3.5. Zydus Lifesciences Ltd Overview, Products and Services, Strategy and Financial Analysis
37. Tofacitinib Market Other Major And Innovative Companies
